Drug Clinical Trials List
Drug Clinical Trials List
| Study Title | Study Sponsor | Status | Study Drug | Trial Phase | Study Protocol Number | Site |
|---|---|---|---|---|---|---|
| SPIMACO Biosimilar Insulin Phase III Study: Clinical Efficacy and Safety | SPIMACO | Ongoing | Fastulin R / Normulin N | 3 | N/A (version 1.4) Aug 2011 | KFMC |
| "Somatostatin as inflow modulator in Adult-to-Adult living donor liver transplantation. A randomized, double-blind, placebo-controlled trial" | King Faisal Specialist Hospital and Research Centre | Ongoing | Somatostatin | 3 | 2191109 | KFSH & RC-R |
| Single arm Phase I/II study of the safety, tolerability and efficacy of the Tocilizumab followed by cisplatin/docetaxel in patients with triple negative locally advanced breast cancer | King Faisal Specialist Hospital and Research Centre | Ongoing | TOCILIZUMAB (ACTEMRA) | 1/2 | 2181156 | KFSH&RC-R |
| Single arm Phase I/II study of the safety, tolerability and efficacy of the investigational anti PD-L1 monoclonal antibody Durvalumab in combination with Paclitaxel in patients with metastatic triple negative PD-L1 positive breast cancer | AstraZeneca | Ongoing | Paclitaxel | 1, 2 | ESR-14-10649 | KFSH & RC-R |
| Safety and Feasibility of CD19 Chimeric Antigen Receptor (CAR) T Cells In Adults with CD19 Positive Relapsed and Refractory Acute Lymphoblastic Leukemia or Lymphoma | KAIMRC | Completed | CD19-CART | 1b | RC20/446/R | NGHA-R |
| S1501 Carvedilol in Preventing Cardiac Toxicity in Patients With Metastatic HER-2-Positive Breast Cancer | SWOG (Southwest Oncology Group) | Ongoing | CARVEDILOL | 3 | S1501 | KFSH & RC-R |
| RELATED HAPLOIDENTICAL HEMATOPOIETIC STEM CELL TRANSPLANTATION IN CHILDREN WITH SYMPTOMATIC SICKLE CELL DISEASE: A PROSPECTIVE STUDY | King Faisal Specialist Hospital and Research Centre | Ongoing | HAPLOIDENTICAL HEMATOPOIETIC STEM CELL TRANSPLANTATION (HSCT) | 3 | 2191237 | KFSH&RC-R |
| Re-EValuating the Inhibition of Stress Erosions and prophylaxis against gastrointestinal bleeding in the critically ill | KAIMRC | Ongoing | pantoprazole | 3 | CT19/009/R | King Abdulaziz Medical City NG (Riyadh) |
| Re-challenge therapy with chemotherapy and panitumumab in metastatic colorectal cancer patients treated with an anti-EGFR therapy in 1st line treatment: a phase II multicentre study. | King Abdullah Medical City, Holy Capital | Ongoing | PANITUMUMAB | 2 | 19-504 | KAMC |
| Randomized, two-way, two- period, single oral dose, open- label, crossover, bioequivalence study to compare Diclofenac Potassium powder for oral solution (50 mg diclofenac potassium) manufactured by Riyadh Pharma versus Catafast® powder for oral solution (50 mg diclofenac potassium) manufactured by Mipharm S.p.A., in healthy subjects under fasting condition. | Saudi Ajal | Ongoing | DICLOFENAC POTASSIUM | 1, BE | 42856 | Saudi Ajal |